Equities analysts expect that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will post ($1.49) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tonix Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.75) and the highest is ($1.23). Tonix Pharmaceuticals posted earnings per share of ($61.00) during the same quarter last year, which suggests a positive year over year growth rate of 97.6%. The business is expected to report its next quarterly earnings report on Monday, March 16th.
On average, analysts expect that Tonix Pharmaceuticals will report full-year earnings of ($15.55) per share for the current financial year, with EPS estimates ranging from ($17.09) to ($14.01). For the next year, analysts forecast that the company will report earnings of ($2.30) per share, with EPS estimates ranging from ($2.49) to ($2.10). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for Tonix Pharmaceuticals.
Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Friday, November 8th. The company reported ($5.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($4.35) by ($1.34).
Separately, ValuEngine downgraded shares of Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th.
NASDAQ:TNXP traded down $0.01 during midday trading on Monday, hitting $1.26. The company’s stock had a trading volume of 640,305 shares, compared to its average volume of 2,710,753. Tonix Pharmaceuticals has a fifty-two week low of $0.86 and a fifty-two week high of $42.00. The firm’s 50 day moving average is $1.19 and its 200-day moving average is $0.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.88 and a quick ratio of 4.88. The firm has a market cap of $7.83 million, a P/E ratio of 0.00 and a beta of 1.03.
A number of large investors have recently modified their holdings of TNXP. Vanguard Group Inc. acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $117,000. Acadian Asset Management LLC increased its holdings in Tonix Pharmaceuticals by 620.0% in the 2nd quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock worth $89,000 after buying an additional 56,516 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $42,000. Institutional investors own 8.99% of the company’s stock.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer’s disease.
Featured Article: What is the Beige Book?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tonix Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.